Exponent Reports Third Quarter of Fiscal Year 2024 Financial Results
Rhea-AI Summary
Exponent (NASDAQ: EXPO) reported Q3 2024 financial results with flat revenues before reimbursements at $125.1 million, while total revenues increased 2% to $136.3 million. Net income grew 6% to $26.0 million ($0.50 per diluted share), and EBITDA margin expanded by 100 basis points to 28.6%. The company saw healthy rebound in consumer electronics sector, offset by challenges in chemicals. Year-to-date results showed 3% growth in revenues before reimbursements to $394.7 million, with net income of $85.4 million ($1.66 per diluted share). The company maintained revenue guidance and raised margin guidance for full-year 2024.
Positive
- Net income increased 6% to $26.0 million in Q3 2024
- EBITDA margin expanded by 100 basis points to 28.6%
- YTD revenues before reimbursements grew 3% to $394.7 million
- Strong cash position with $219.7 million in cash and cash equivalents
- Improved utilization rate of 75% in first nine months of 2024
Negative
- Flat Q3 revenues before reimbursements year-over-year
- Environmental and health segment revenues declined 6% in Q3
- Persistent challenges in chemicals sector affecting performance
News Market Reaction
On the day this news was published, EXPO declined 8.88%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the third quarter of fiscal year 2024 ended September 27, 2024.
“For the third consecutive quarter Exponent has delivered significantly improved utilization year over year, reflecting our ongoing focus on effective resource management and alignment with market demand. As expected, third quarter revenues before reimbursements were flat year-over-year, however we delivered a
“As industries transform at breakneck speed, the nexus between innovation and safety, health and environmental impacts grows increasingly complex. These concerns are at the forefront of global priorities, reinforcing the need for our critical insights and expertise. Looking ahead, we are focused on adding talent and expanding our capabilities to meet our customers’ needs across industries and throughout the product lifecycle,” Dr. Corrigan continued.
Third Quarter Financial Results
Total revenues and revenues before reimbursements for the third quarter of 2024 increased
Net income increased to
EBITDA1 increased to
Year to Date Financial Results
Total revenues and revenues before reimbursements for the first three quarters of 2024 increased
Net income was
EBITDA1 increased to
In a separate press release today, Exponent announced its quarterly cash dividend of
Business Overview
Exponent’s engineering and other scientific segment represented
Exponent’s environmental and health segment represented
Business Outlook
“Our ability to align our operating model with market demand resulted in
For the fourth quarter of 2024, which includes the impact of an additional week, as compared to the same period one year prior, Exponent anticipates:
- Revenues before reimbursements to grow in the mid-single digits; and,
- EBITDA1 to be
23.5% to24.5% of revenues before reimbursements.
For the fiscal year 2024, which includes the impact of an additional week, as compared to the same period one year prior, Exponent anticipates:
- Revenues before reimbursements to grow in the low to mid-single digits; and,
- EBITDA1 to be
27.9% to28.1% of revenues before reimbursements.
“Exponent excels in navigating the complexities inherent in innovation and technology. We are encouraged by the long-term demand drivers that heighten the need for our differentiated capabilities and critical insights. Our focus remains on anticipating the evolving needs of our clients throughout the product lifecycle while delivering sustained profitable growth and lasting value for our shareholders,” concluded Dr. Corrigan.
Today's Conference Call Information
Exponent will discuss its financial results in more detail on a conference call today, Thursday, October 24, 2024, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (844) 481-2781 or (412) 317-0672. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (877) 344-7529 or (412) 317-0088 and entering passcode 1389454#.
Use of non-GAAP Financial Measures 1
EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation, and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income, and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present, and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.
Exponent has provided its outlook regarding EBITDA as a percentage of revenues before reimbursements. The Company has not reconciled this non-GAAP financial measure to the corresponding GAAP financial measure because guidance for the various reconciling items is not provided and the Company is unable to estimate with reasonable certainty the effect of these items without unreasonable effort. For example, the Company is unable to estimate with reasonable certainty the impact of equity awards on Exponent’s taxes without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on Exponent’s results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this release is provided in the financial tables at the end of this release.
About Exponent
Exponent brings together 90+ technical disciplines and 950+ consultants to help our clients navigate the increasing complexity of more than a dozen industries, connecting decades of pioneering work in failure analysis to develop solutions for a safer, healthier, more sustainable world.
Exponent’s consultants deliver the highest value by leveraging multidisciplinary expertise and resources from across Exponent’s offices in North America, Asia, and Europe. Exponent’s consultants, laboratories, databases, and computing resources work seamlessly together around the globe, enabling us to produce the breakthrough insights needed to help multinational companies, startups, law firms, insurance companies, governments, and society respond to incidents and push their products and processes forward.
Exponent may be reached at (888) 656-EXPO, info@exponent.com, or www.exponent.com.
Forward Looking Statements
This news release contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. When used in this document and in the documents incorporated herein by reference, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in generally applicable and industry-specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading “Risk Factors” and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.
Source: Exponent, Inc.
| EXPONENT, INC. | |||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||||||||
| For the Quarters Ended September 27, 2024 and September 29, 2023 | |||||||||||||||||||
| (unaudited) | |||||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||||
| Quarter Ended | Nine Months Ended | ||||||||||||||||||
| September 27, | September 29, | September 27, | September 29, | ||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||
| Revenues | |||||||||||||||||||
| Revenues before reimbursements | $ | 125,085 | $ | 124,959 | $ | 394,726 | $ | 383,317 | |||||||||||
| Reimbursements | 11,194 | 8,377 | 27,022 | 30,549 | |||||||||||||||
| Revenues | 136,279 | 133,336 | 421,748 | 413,866 | |||||||||||||||
| Operating expenses | |||||||||||||||||||
| Compensation and related expenses | 81,954 | 74,011 | 251,747 | 241,028 | |||||||||||||||
| Other operating expenses | 11,975 | 10,997 | 33,691 | 30,863 | |||||||||||||||
| Reimbursable expenses | 11,194 | 8,377 | 27,022 | 30,549 | |||||||||||||||
| General and administrative expenses | 5,309 | 6,018 | 16,984 | 18,498 | |||||||||||||||
| 110,432 | 99,403 | 329,444 | 320,938 | ||||||||||||||||
| Operating income | 25,847 | 33,933 | 92,304 | 92,928 | |||||||||||||||
| Other income (expense), net | |||||||||||||||||||
| Interest income, net | 2,559 | 1,858 | 7,416 | 5,221 | |||||||||||||||
| Miscellaneous income (expense), net | 7,531 | (1,774 | ) | 16,322 | 7,659 | ||||||||||||||
| 10,090 | 84 | 23,738 | 12,880 | ||||||||||||||||
| Income before income taxes | 35,937 | 34,017 | 116,042 | 105,808 | |||||||||||||||
| Income taxes | 9,893 | 9,479 | 30,629 | 26,398 | |||||||||||||||
| Net income | $ | 26,044 | $ | 24,538 | $ | 85,413 | $ | 79,410 | |||||||||||
| Net income per share: | |||||||||||||||||||
| Basic | $ | 0.51 | $ | 0.48 | $ | 1.67 | $ | 1.55 | |||||||||||
| Diluted | $ | 0.50 | $ | 0.48 | $ | 1.66 | $ | 1.54 | |||||||||||
| Shares used in per share computations: | |||||||||||||||||||
| Basic | 51,177 | 51,203 | 51,098 | 51,197 | |||||||||||||||
| Diluted | 51,622 | 51,645 | 51,527 | 51,680 | |||||||||||||||
| EXPONENT, INC. | |||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||||
| September 27, 2024 and December 29, 2023 | |||||||||||||
| (unaudited) | |||||||||||||
| (in thousands) | |||||||||||||
| September 27, | December 29, | ||||||||||||
| 2024 | 2023 | ||||||||||||
| Assets | |||||||||||||
| Current assets: | |||||||||||||
| Cash and cash equivalents | $ | 219,708 | $ | 187,150 | |||||||||
| Accounts receivable, net | 168,618 | 167,360 | |||||||||||
| Prepaid expenses and other assets | 24,255 | 25,022 | |||||||||||
| Total current assets | 412,581 | 379,532 | |||||||||||
| Property, equipment and leasehold improvements, net | 72,862 | 75,318 | |||||||||||
| Operating lease right-of-use asset | 75,797 | 24,600 | |||||||||||
| Goodwill | 8,607 | 8,607 | |||||||||||
| Other assets | 174,218 | 158,720 | |||||||||||
| $ | 744,065 | $ | 646,777 | ||||||||||
| Liabilities and Stockholders' Equity | |||||||||||||
| Current liabilities: | |||||||||||||
| Accounts payable and accrued liabilities | $ | 22,646 | $ | 22,125 | |||||||||
| Accrued payroll and employee benefits | 96,738 | 111,773 | |||||||||||
| Deferred revenues | 13,414 | 21,709 | |||||||||||
| Operating lease liability | 4,940 | 6,302 | |||||||||||
| Total current liabilities | 137,738 | 161,909 | |||||||||||
| Other liabilities | 120,131 | 106,824 | |||||||||||
| Operating lease liability | 75,922 | 21,959 | |||||||||||
| Total liabilities | 333,791 | 290,692 | |||||||||||
| Stockholders' equity: | |||||||||||||
| Common stock | 66 | 66 | |||||||||||
| Additional paid-in capital | 342,301 | 321,448 | |||||||||||
| Accumulated other comprehensive loss | (1,606 | ) | (2,977 | ) | |||||||||
| Retained earnings | 614,991 | 574,082 | |||||||||||
| Treasury stock, at cost | (545,478 | ) | (536,534 | ) | |||||||||
| Total stockholders' equity | 410,274 | 356,085 | |||||||||||
| $ | 744,065 | $ | 646,777 | ||||||||||
| EXPONENT, INC. | |||||||||||||||||||||
| EBITDA and EBITDAS (1) | |||||||||||||||||||||
| For the Quarters Ended September 27, 2024 and September 29, 2023 | |||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||
| Quarter Ended | Nine Months Ended | ||||||||||||||||||||
| September 27, | September 29, | September 27, | September 29, | ||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||
| Net Income | $ | 26,044 | $ | 24,538 | $ | 85,413 | $ | 79,410 | |||||||||||||
| Add back (subtract): | |||||||||||||||||||||
| Income taxes | 9,893 | 9,479 | 30,629 | 26,398 | |||||||||||||||||
| Interest income, net | (2,559 | ) | (1,858 | ) | (7,416 | ) | (5,221 | ) | |||||||||||||
| Depreciation and amortization | 2,389 | 2,361 | 7,199 | 6,535 | |||||||||||||||||
| EBITDA (1) | 35,767 | 34,520 | 115,825 | 107,122 | |||||||||||||||||
| Stock-based compensation | 5,465 | 4,891 | 18,382 | 17,177 | |||||||||||||||||
| EBITDAS (1) | $ | 41,232 | $ | 39,411 | $ | 134,207 | $ | 124,299 | |||||||||||||
| (1) EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. | |||||||||||||||||||||
FAQ
What was Exponent's (EXPO) earnings per share in Q3 2024?
How much revenue did Exponent (EXPO) generate in Q3 2024?
What was Exponent's (EXPO) EBITDA margin in Q3 2024?
What is Exponent's (EXPO) quarterly dividend payment for Q3 2024?
